Barclays Appoints Jefferson Rives as a Managing Director in Healthcare Investment Banking
16 Novembro 2021 - 1:37PM
Business Wire
Barclays announces the appointment of Jefferson Rives as a
Managing Director in Healthcare Investment Banking. Mr. Rives will
be based in New York, and will focus on healthcare services
including IT, payer and pharma supply chain. He will report to Rick
Landgarten, Global Head of Healthcare & Real Estate Groups at
Barclays.
Mr. Rives joins Barclays with over fifteen years of industry
experience, most recently as a Managing Director in Healthcare
Investment Banking at Wells Fargo. Prior to joining Wells Fargo in
2015, Mr. Rives worked in the Global Healthcare Banking team at
Morgan Stanley, and before that from 2011 worked at Jefferies &
Company in the Global Healthcare Group. Mr. Rives has been involved
in corporate advisory and financing transactions totaling over
$175bn in value during his career to date, and has extensive
experience in HCIT, Pharmacy Supply Chain, and Employer, Payer, and
Provider Services. He has led the origination and execution of a
number of high-profile transactions, including advising PANTHERx
Rare Pharmacy on its sale to Centene, advising MeMD on the
company’s sale to Walmart, and serving as bookrunner on equity
deals for Phreesia, One Medical, Omnicell, Allscripts, and Change
Healthcare.
“Jefferson has outstanding knowledge of the healthcare services
space, and his extensive transactional experience and deep roster
of key relationships will deliver great value for our clients,”
said Rick Landgarten, Global Head of Healthcare & Real Estate
Groups. “We look forward to succeeding together as a team, and
further accelerating our HCIT and broader Healthcare business
momentum.”
Mr. Rives’ hire follows Barclays’ recent appointments of Amit
Tyagi as a Managing Director focusing on the Tools and Diagnostics
sector, and Naeem Merchant as a Managing Director focusing on the
Pharmaceutical Services and IT sectors.
Barclays has performed lead roles in a number of recent
transactions of note in the Healthcare Banking space, including
serving as financial advisor to Thermo Fisher Scientific on their
pending $21bn acquisition of PPD, and acting as financial advisor
to Centene Corporation in the company’s $3.1bn acquisition of
Magellan Health, Inc. Barclays acted as financial advisor to
Kindred at Home on their sale to Humana, and served as financial
advisor to HMS on the company’s sale to Veritas Capital-backed
Gainwell Technologies for $3.4bn. Barclays also acted as lead left
bookrunner and stabilization agent on a $388mm follow on offering
for R1 RCM Inc. In addition, Barclays has performed key roles in
several recent IPOs of note, including serving as a senior active
bookrunner on a $649mm IPO for Signify Health, Inc., as an active
bookrunner on a $924mm IPO for Bright Health Group, Inc., and as an
active bookrunner on a $1.3bn IPO for GoodRx Holdings, Inc.
Barclays is a British universal bank. We are diversified by
business, by different types of customer and client, and geography.
Our businesses include consumer banking and payments operations
around the world, as well as a top-tier, full service, global
corporate and investment bank, all of which are supported by our
service company which provides technology, operations and
functional services across the Group. For further information about
Barclays, please visit our website www.barclays.com. Barclays
offers investment banking products and services in the US through
Barclays Capital Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211116006143/en/
Press: Andrew Smith +1 212 412 7521
andrew.x.smith@barclays.com
Barclays (LSE:BARC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Barclays (LSE:BARC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024